Abstract Protein modeling and molecular dynamics hold a unique toolset to aide in the characterization of clinical variants that may result in disease. Not only do these techniques offer the ability to study under characterized proteins, but they do this with the speed that is needed for time-sensitive clinical cases. In this paper we retrospectively study a clinical variant in the XIAP protein, C203Y, while addressing additional variants seen in patients with similar gastrointestinal phenotypes as the C203Y mutation. In agreement with the clinical tests performed on the C203Y patient, protein modeling and molecular dynamics suggest that direct interactions with RIPK2 and Caspase3 are altered by the C203Y mutation and subsequent loss of Zn coordination in the second BIR domain of XIAP. Interestingly, the variant does not appear to alter interactions with SMAC, resulting in further damage to the caspase and NOD2 pathways. To expand the computational strategy designed when studying XIAP, we have applied the molecular modeling tools to a list of 140 variants seen in CFTR associated with cystic fibrosis, and a list of undiagnosed variants in 17 different genes. This paper shows the exciting applications of molecular modeling in the classification and characterization of genetic variants identified in next generation sequencing.
Introduction
The completion of the human genome was one of the biggest breakthroughs in human knowledge. Following its completion, technology has continued to advance, which has now allowed sequencing of a genome for only a few thousand dollars. These prices will make genomic sequencing common practice, cheaper than many clinical tests currently being used. The human sequencing so far has identified millions of variants, with characterization of these variants only in its infancy. The influx of this new genomic data is likely to continue transforming fields such as biochemistry and molecular biology. Genomes are currently being employed in understanding common conditions such as cardiovascular disease [39] or cancer [11] , with the results challenging at both the individual genome and at an epidemiological level. For rare diseases, however, the use of genomic sequencing is becoming a viable option in clinical identification [14] . With the cost of sequencing a genome at several thousand dollars, utilization of whole genome sequencing could supplement or supersede some expensive clinical tests.
One of the first cases in which whole exome sequencing was used to treat a patient, was in a male child suffering from a Crohn's like inflammatory bowel disease (IBD) [42] . Sequencing revealed a single amino acid missense mutation (C203Y) in a protein, XIAP. This case reached wide audiences, gaining a voice in popular media through stories such as the Pulitzer prize winning, BOne in a billion: a boy's life, a medical mystery.^Variants in XIAP were not previously associated with gastrointestinal (GI) disease, but more commonly seen in X-linked lymphoproliferative syndrome [30] . XIAP is located on the X-chromosome, and therefore the single copy of XIAP in a male child with a loss of function mutation (hemizygous) can result in disease. Following the identification of this variant in the XIAP protein, subsequent variations of XIAP have been discovered in patients with IBD, celiaclike disease, Crohn's-like disease, severe infectious mononucleosis, and hemophagocytic lymphohistiocytosis (HLH) [35, 36, 41] .
XIAP has several characterized functions, most notably the inhibition of activated Caspases [9] and regulation of NOD1/2 signaling [5] through interaction with RIPK2 [17] . Both Caspase inhibition and NOD signaling of XIAP can be blocked by the release of the SMAC/Diablo protein from the mitochondria [4, 17, 33] (Fig. 1) . In many cancer phenotypes, activation of Caspase proteins has the potential to result in apoptotic cell death [21] . Therefore, many groups have developed SMAC mimetics in hopes of blocking XIAP inhibition of Caspase and autophagy, allowing for selective cell death in cancer cells [13, 21, 23, 32] . However, some SMAC mimetics additionally block XIAP activation of the NOD signally pathway [5, 17] , suggesting some potential immunocompetence in treating cancer patients with SMAC mimetics. Additionally, the role of XIAP somatic mutations in cancer has not been assessed for their ability to endogenously alter apoptosis of cancer.
The continual increase in genomic sequencing has shown practical clinical use [14] ; however, there is a need for the development of new tools in the analysis and characterization of variants in perturbing molecular pathways. From a variant stand point, there exist many tools to address the impact of a variant relative to species' evolution, thousands of additionally sequenced human exomes/genomes, and known variants seen in diseases. Yet, these tools currently identify a large fraction of variants as Bvariants of uncertain significance( VUS) or Bgenes of uncertain significance^(GUS), in which no clinical decision can be made, often due to the lack of knowledge for that particular gene. An area that is ideal for use in characterizing VUS and GUS, but currently underutilized, is molecular modeling and dynamics. We hypothesize that molecular modeling and dynamics will serve as a valuable tool in understanding VUS and GUS of genomic sequencing. The XIAP variant previously discovered by our group, C203Y, was initially a VUS that required months of benchtop characterization, delaying treatment for a patient in extreme need of treatment options. Using knowledge of XIAP modeling and dynamics, we hope to gain insights into XIAP function while additionally showing the practical application of molecular modeling and dynamics in characterization of VUS and GUS from genomic sequencing.
The XIAP protein has several known structures and well characterized pathways, making it a strong candidate to begin utilizing the tools of molecular modeling and dynamics in understanding genetic variation. Much like the Enterprise served as the tool for Jean-Luc Picard and crew to understand space in Star Trek: The Next Generation; molecular modeling will serve as an enterprise for researchers to understand the space in which variants of next generation sequencing result in disease. Using molecular modeling, sequence analysis, and structures, we have addressed known mutations for XIAP as to their potential perturbation in molecular interactions, ultimately suggesting potential sites in XIAP that may be novel to design inhibitors to, and suggest novel drug development for treatment options in the future. Further, while studying the role of XIAP in silico, it was noted that the tools designed had the unique ability to functionally predict hypotheses for genetic variants; therefore, the tools were next applied to a list SMAC (red), also known as Diablo, is released from the mitochondria as a result of apoptotic signaling, which then displaces the XIAP-Caspase 3 interaction, allowing induction of apoptosis. In addition to Caspase regulation, XIAP is known to interact and regulate RIPK2 (cyan) in the NOD pathway of bacterial activation of rare genetic disease variants from cystic fibrosis to undiagnosed diseases. The field of molecular modeling holds great potential in generating testable molecular hypotheses for the outcome of genetic variants, making it a critical tool in the arsenal of weapons to combat genetic diseases in the wholegenome era.
Methods

Structural analysis of XIAP
Structures of XIAP were identified by BLAST analysis with the human XIAP sequence against the protein data bank (PDB). A full atomic model was created by joining the BIR1 (PDB file 2pop, amino acids 10-100), BIR2 (1i3o, amino acids 124-240), BIR3 (1f9x, amino acids 241-356), UBA (2kna, amino acids 357-449) and the RING-type (4ic2, amino acids 429-497) domains with an ab initio model prediction using QUARK [43] for amino acids 101-123. The domains were placed together so that interactions between XIAP with TAB1 (PDB file 2pop), Caspase3/7 (1i3o and 1i4o), Caspase9/SMAC (1 g73 and 1nw9), and the RING-type dimers (4ic2) did not result in steric clash between the binding partners. Domain alignments with protein interaction partners was performed using the MUSTANG algorithm [16] . Using the compiled model, homology modeling was performed using the sequence of human (Uniprot P98170, amino acids1-497), mouse (Q60989, 1-496), and rat (Q9R0I6, 1-496) XIAP with YASARA. Amino acids that were identified to vary in XIAP in disease patients were then identified on the structure of the full XIAP, allowing for rapid identification of how the variants could perturb interaction with various proteins. To determine SMAC binding with the BIR2 or BIR3 domain, the known structure of BIR3 interaction with SMAC (PDB file 1 g73) had the BIR3 homology modeled to the sequence of the BIR2 domain using YASARA, followed by energy minimizations of either BIR3/SMAC or BIR2/SMAC using the Amber03 [8] force field with 0.997 g/mL water. Binding energy was then calculated using YASARA [18] with AMBER03 force field and wall boundary, which calculates the sum of all potential energies of the object and soup, and subtracts the potential energy value for the soup, with a positive value suggesting energy for interaction between objects.
Sequence analysis of BIR domain proteins
Sequences were obtained for human (h) Survivin (Uniprot O15392), Bruce (Q9NR09), cIAP1 (Q13490), cIAP2 (Q13489), XIAP (P98170), ILP2 (Q96P09), MLIAP (Q96CA5), and NAIP (Q13075) with the individual BIR domains parsed. XIAP sequences for Drosophila (d, I6L9G1), Gallus ©, F6TJT0), Xenopus (x, A5D8Q0), Mus (m, Q60989), and Rattus ®, Q9R0I6) were additionally used. Sequence alignments were performed using Clustal Omega [34] with default settings. A phylogenetic analysis of the domains was performed using maximum likelihood with the JTT matrix [15] and a consensus of 1000 bootstrap replicates [10] using MEGA5 [38] . The initial tree for the heuristic search was obtained automatically by applying Neighbor-Join (NJ) and BioNJ algorithms to a matrix of pairwise distances estimated using a JTT model, and then selecting the topology with superior log likelihood value. The analysis involved 31 amino acid sequences for 66 amino acids. Variants of XIAP associated with disease were identified in published literature, utilizing only single amino acid changes (including mutations to stop codons (X) and not mutations that result in a frameshift.
Molecular dynamic simulations
Molecular dynamic (MD) simulations were performed on two protein complexes, XIAP interaction with Caspase-3, or XIAP interaction with the top docking prediction of RIPK2. For the XIAP-Caspase-3 md simulation, PDB structure 1i3o was cleaned in YASARA, removing all water and adding hydrogen atoms to all molecules. The structure was placed in a simulation box of 118,70,79 Å (x,y,z axes) and cell neutralization was performed using 0.9% mass fraction of cations and anions, pH of 7.4, and water density of 0.997 g/mL. The structure was energy minimized using the Amber03 [8] force field to reduce crystal packing forces of the structure. Individual molecules of the file were then separated into individual objects joining the two subunits of Caspase-3 into a single object and the BIR2 domain of XIAP with its respective Zn ion. The Zn ion was held in place during the simulation using constrained distances of the Zn from its four connecting residues, using a dummy atom for the Zn and four springs of 1.5 Å to hold all four points of coordination together. The md simulations were then performed for 12.5 ns using the default md_run macro in YASARA. Trajectories were analyzed using the md_analyze and md_analyzeres macros (http://www. yasara.org/macros). In addition to the wild type MD simulations, three other simulations were performed. First, the cysteine 203 (Cys,C) of XIAP was substituted with a tyrosine (Tyr,Y) to create XIAP C203Y with the three additional contact points with the Zn ion left constrained. Second, the Zn was removed and all four contacts no longer restrained, but the cysteine was left at amino acid 203 (XIAPZn). Lastly the C203Y mutation was made in addition to removal of the Zn ion (XIAP C203Y-Zn). All simulations were performed for 12.5 ns.
Docking of XIAP to RIPK2 was performed using the PDB structure 4c8b of human RIPK2. The structure was parsed down to a single domain of RIPK2 and had missing loops modeled using YASARA. The remaining structure was placed in a 60 Å simulation square, and rigid body docking of the XIAP BIR2 domain was performed using AutoDock VINA [40] with ten dockings performed on five separate rotamer ensembles of RIPK2. Following calculation of binding energy, the top docking conformation was inserted into a simulation square extending 5 Å from all atoms, and the cell was neutralized with the same conditions used for Caspase-3 analysis. The protein complex was then energy minimized and MD simulations performed for 15 ns. The complex was simulated as the wild type or as the XIAP C203Y mutation with the Zn ion removed (XIAP C203Y-Zn).
Generation of sequence-to-structure-to-function data for rare disease variants
The sequence-to-structure-to-function (SSF) analysis begins with two parallel processes: a protein structural assessment and an evolutionary sequence analysis. To begin, the variant in a protein is assessed for location within domains, motifs, or regions with likelihood of structural order/disorder using MobiDB [7] . The domain, motif, or ordered regions are structurally assessed for homology of a protein to known structures in the PDB, using BLAST. All proteins with >30% homology, including ligands (DNA, RNA, proteins, and compounds), were structurally aligned using MUSTANG algorithm [16] . The variant site was highlighted in the graphical models to visually screen for impact of a specific variant on ligand sites.
Using the results of the structural assessment, informed decisions can be made regarding how the protein will be structurally modeled. For homologous templates (>70% homology for known protein structures) and metal coordinated domains, homology modeling was used with YASARA [19] , using a knowledge-based force field minimization of five merged models. For proteins with some structural knowledge (>30% homology), a hybrid threading approach was used with I-TASSER [31] . Where no templates were known, ab initio modeling was used for small proteins <200 amino acids with QUARK [43] , and I-TASSER was used when the protein is >200 amino acids. Testing for all models was under energy minimized physiological conditions. Soluble proteins were modeled in 0.997 g/mL water with 0.9% mass fraction NaCl and a pH of 7.4 (for cell neutralization and pKa prediction). Membrane proteins were modeled in a PEA lipid membrane with water and NaCl (as above) on either side of the membrane, and allowed to equilibrate for 250 ps simulation. Models from each of these structure prediction steps were standardized by minimizing energy using the knowledge-based force field YASARA2 [19] . The structural z-score, cis-peptide bond count, and number of wrong isomer predictions were used to determine the best model relative to properties of known protein structures (bond distances, torsion angles, dihedrals, electrostatics, and Van der Waals forces). Homology modeling (YASARA [19] ) was then used to generate the protein of interest in other species (such as rat and mouse) to help validate the conservation of fold space. Both sequence homology and structural alignment (using MUSTANG) were determined for multiple species models. Multiple species modeling can also help guide selection of species for physiological models for future testing of protein variants [27] .
For the evolutionary sequence analysis portion of the SSF, open reading frame (ORF) sequences from NCBI were aligned with ClustalW [20] . Amino acid sequence alignment (FASTA file) was combined with the protein model using ConSurf [1] to display conserved amino acids on the threedimensional protein. This allowed visualization of the conservation of the amino acid of interest, as well as those amino Structures highlighted in yellow were used for modeling the complete XIAP structure (Fig. 2b) and those in red used to model XIAP-protein interactions ( Fig. 2c-d ).
acids located around the site of interest, which increases one's ability to predict functionally conserved regions of the protein.
As amino acid conservation is not always indicative of evolutionary selection, RNA sequence alignments were used to determine the codon selection rate using dN-dS [25, 37] , calculated in MEGA5 [38] -a metric that tells how often a codon change results in non-synonymous (dN) mutations relative to codon changes that result in synonymous (dS) mutations. A negative value for the difference between the two variant types (dN-dS) suggests that, throughout evolution, there is pressure to maintain the amino acid even though the DNA sequence varies. The final step was to determine conserved posttranslational modification sites located near a variant of interest using a variety of programs [2, 3, 22, 28, 29, 44, 45] , conserved linear motifs that may be altered by the variant using ELM [6] , and interaction networks for the protein using STRING9.1 [12] . The use of known protein interactions of STRING and ELM in combination with the structural assessment/ConSurf analysis allows for docking approaches of protein-protein/DNA/ RNA interactions (using rigid docking with multiple ensembles in AutoDock [24] , followed by energy minimizations in physiological conditions [26] ). MD simulations using AMBER03 force field [8] in YASARA allowed for computational testing of the variants ability to perturb the protein/ DNA/RNA interactions and/or protein folding.
Results
Structural model of the complete XIAP protein
Single amino acid mutations that have been associated with various disease phenotypes (red and blue) or in the Catalog of Somatic Mutations in Cancer (COSMIC) database (green) were identified on the domains of XIAP (Fig. 2a) . XIAP contains a high density of disease variants in the BIR2 domain, while a high number of variants from COSMIC are found in the UBA domain. To understand where the variants are located on the structure, a complete model was built for human (Fig. 2b) , mouse and rat XIAP based on known structures (Table 1) such that the interactions with TAB1, Caspase3/7, Caspase 9/SMAC, and the RING dimer were maintained (Fig. 2c-d) . The structures between human, mouse, and rat aligned with an average of 91.53% homology, with only a 0.42 Å carbon alpha root-mean squared deviation (RMSD) between the structures. In addition the structural Z-scores were −0.68, −0.76, and −0.83 relative to other PDB structures, suggesting accurate predictions of the global structure, with anything > −2 considered a good model. The disease variants were then identified on the full structure (Fig. 2b) , allowing for rapid identification of how all variants may alter protein packing or protein-protein interaction.
Evolution of the BIR domain
The XIAP protein contains three separate BIR domains. In humans, a total of eight BIR containing proteins has been identified, with a total of 16 separate BIR domains. Each of these BIR domains were parsed, aligned, and a phylogenetic tree created (Fig. 3a) . Across species, the BIR1 and BIR3 domain of XIAP cluster separately, with the Bir2 domain clustering close to the human cIAP1 and cIAP2 BIR2 domains. Sequence analysis revealed eight amino acids that are 100% conserved (red), and several additionally functionally conserved (cyan) in all human BIR domains (Fig. 3b) . To identify if there are any amino acids that are specific and conserved in the second BIR domain of XIAP, sequence alignments from multiple species for XIAP were performed (Fig. 3c) ; 18 amino acids that are conserved in the BIR2 domain of XIAP are also conserved in other human BIR domains (red and cyan), while 6 amino acids are conserved in all three of the XIAP BIR domains but not all human BIR-containing proteins (magenta). The genetic variant first identified in the child with the Crohn's like disease was a C203Y mutation [42] . This amino acid is 100% conserved in all BIR domains and is known to contribute to the four coordinated Zn binding, of which are four of the eight 100% conserved amino acids (red) of the BIR domain. Amino acids 166 and 188, which have variants associated with disease, are also 100% conserved in all BIR domains. Amino acids 173 and 207, which contain disease associated variants, are functionally conserved in all BIR domains; 21 amino Fig. 3a-f Sequence analysis of BIR domains. a Phylogenetic analysis using maximum likelihood for human (h), mouse (m), rat ®), chicken ©), Xenopus (x), and Drosophila (d) proteins containing 31 total BIR domains. The names for each are shown with the first letter representing the species, followed by the protein name, sometimes containing a.x where x is the number of the BIR domain for that protein, then the Uniprot accession number, and finally the amino acids from the protein used for the analysis. Values at each node of the tree represent the percent of 1000 bootstrap analyses matching the tree shown. b, c Sequence alignments of the human Bir domains (b), with the Bir domains listed for human (h), mouse (m), rat ®), chicken ©), Xenopus (x), and Drosophila (d) for each of the three Bir domains of XIAP (c). Amino acids highlighted in red are 100% conserved in all Bir domains, those in cyan are functionally conserved in the Bir domains, those in magenta are conserved in all three of the Bir domains of XIAP and those in green are conserved only in the XIAP Bir2 domain across the species. The location of the C203Y is 100% conserved in all Bir domains. d Coloring of the sequence alignment in b and c shown on the structure of Bir2 from XIAP. Amino acids that are surface-exposed and specific to the XIAP Bir 2 domain are labeled. Those shown in yellow (Q197 and F228) were 100% conserved in multiple species of Bir2 domains but were not seen in other XIAP Bir domains (1/3). e The molecular surface of the Bir2 domain of XIAP showing high probability of protein interaction sites. f Disease-associated variants in the Bir2 domain from Fig. 2a shown on the structure with conservation color. Those variants that fall at highly conserved sites are shown as side chains and labeled acids were found conserved in the BIR2 domain of XIAP but not in the other XIAP BIR domains (green).
To understand the specificity of the XIAP BIR2 domain relative to other BIR domain proteins, a BIR domain structure was used to map the conservation from the sequence alignment above. Several variants that were highly conserved in the BIR2 domain (green) map to the surface of the protein, suggesting potential protein interaction (Fig. 3d, e) . Two amino acids, Q197 and F228, both map to the surface of the BIR2 domain and are conserved in all species XIAP BIR2 domains and not in any other human BIR domain. Using the same protein structure, the genetic variants in the BIR2 domain of XIAP associated with disease were also identified to determine their contribution to protein folding or surface exposure (Fig. 3f) .
XIAP and caspase
Previously, the XIAP BIR2 domain was crystalized with Caspase-3 (Fig. 4a) . MD simulations were performed either on the wild type BIR2 domain, with the C203Y mutation, removal of the Zn ion or C203Y without Zn (Fig. 4b,c) . The global movement of XIAP was most strongly perturbed in the C203Y mutation (red, Fig. 4b) , not altering any of the protein dynamics of Caspase3, but altering a stretch of amino acids in XIAP around the C203Y mutation (Fig. 4c) . These results suggest that the removal of the Zn did not perturb interaction of the two proteins as a result of the high binding energy between XIAP and Caspase3, with some perturbation following the C203Y mutation only as a result of the insertion of a Tyr that is restrained in global positioning due to the Zn. Thus, modeling approaches independent of protein-protein interacts were needed to determine the outcomes of the C203Y mutation, and suggest that, when assessing single point mutations using dynamics, considerations need to be placed first on large changes to structural conformation.
Unlike most Zn finger proteins, and other Zn binding domains that contain few hydrophobic amino acids, the BIR domain contains strong hydrophobic packing with the Zn ion coordinating a hydrophilic region resulting in the surface exposure of several hydrophobic amino acids for protein interactions. Ab initio modeling independent of the known BIR2 structures confers hydrophobic collapse independent of the Zn coordination (Fig. 4d) . Contrary to the possibility that the C203Y and resulting loss of Zn coordination leads to complete unfolding of the molecule, it appears that the surface-exposed hydrophobic amino acids collapse internally, resulting in a loss of surface-exposed contacts. Utilizing this ab initio model, we next sought to address changes in the binding properties to several other XIAP-interactions.
XIAP and RIPK2
One area where current structural work cannot help in the understanding of XIAP genetic variants is regulation of the NOD2 pathway through interaction with RIPK2 (Fig. 5a ). To begin predictions to allow analysis, in silico rigid body AutoDock experiments were used to predict the most likely conformation of XIAP interaction with RIPK2. Two clustering regions were found based on the docking with the highest and second highest binding energy conformations in the same cluster (Fig. 5b) . This binding conformation, when energy minimized, provides numerous contact points between the two proteins with several variants found at the interface (Fig. 5c) . The C203Y mutation and loss of Zn binding results in the loss of several amino acid contacts, with MD simulations (Fig. 5d ) confirming perturbations to two regions of XIAP following the mutation.
XIAP and SMAC
The known interaction of XIAP to SMAC occurs through a dimer of the SMAC protein with two separate XIAP domains (Fig. 6a) . One of the two BIR3 domains of the known structure was mutated to the BIR2 sequence and energy minimized. The physical constraints between the two domains of XIAP in this structure place the N and Ctermini 47 Å apart. Having a 180°rotation on the Omega, Phi, and, Psi bonds of a peptide, maximizing the distance covered by a peptide chain, yields a distance of only 3.6 Å between nitrogen atoms. A gap of 11 amino acids is seen between the two BIR domains interacting with SMAC. Therefore it is physically impossible (maximum of 39.6 Å) to cover the minimum distance (47 Å) between the domains. This is strong evidence that a single molecule of XIAP could not simultaneously have the dimer of SMAC bind to both the BIR2 and BIR3 domains without significant structural alteration to the BIR domains. Therefore, we utilized the individual domains to calculate binding energy with SMAC for both BIR2 and BIR3 (Fig. 6b) . Interestingly, four COSMIC variants (L256I, L256V, N259S, and M262I) in the BIR3 domain map directly to the interface of binding with SMAC. For the BIR2 domain, the C203Y mutation would alter only slight contacts with SMAC (Fig. 6c) . 
Altered XIAP protein interactions
Utilizing the ab initio model of the XIAP C203Y protein above (Fig. 4d) , we assessed the theoretical binding energies for wt XIAP (left) or the C203Y variant (right) to Caspase 3 ( Fig. 7a), RIPK2 (Fig. 7b) , or SMAC (Fig. 7c) . The binding energies are greatly altered for XIAP C203Y for binding to Caspase 3 (wt = 418 kcal mol the patient will alter interactions with two of the three macromolecules. Maintaining interaction with SMAC suggests further perturbation in the decrease of NF-kappa-B activation, and an increase in Caspase3 apoptotic signaling (Fig. 1) . A representative video can be seen on our YouTube channel showing all models and interactions (https://www.youtube. com/watch?v=FPQPXByeUGs&t=11s).
CFTR variants modeled
While developing a way to computationally analyze XIAP variants, the workflow has been developed into a computational pipeline that can be applied to many additional variants for rare and undiagnosed diseases (Fig. 8) . We developed what we call our deep Sequence-to-Structure-to-Function analysis (dSSFa). This was applied to looking at both one gene with a large number of variants (CFTR), and also a list of genes with newly identified variants potentially associated with rare diseases. For CFTR, we looked at the structural modeling, protein dynamics, and conservation of 140 amino acid mutations that are associated with cystic fibrosis (Supplemental Table S1 ). Figure 8 shows the development of our dSSFa tools highlighted for CFTR variant analysis. Models were generated using I-TASSER for the full length CFTR, which were then inserted into a lipid membrane, and water was then added to both the extra and intracellular portions of the simulation square. The model was then run for 4 ns simulation, in which all of the protein variants could be assessed for movement in a wildtype protein. Each mutation was then created, followed by energy minimization. An evolutionary analysis for CFTR was then performed, generating protein models for human, mouse, and rat. ORF analysis was then performed, allowing identification of linear motifs and the conservation scores around any variant. Finally, a ConSurf map of our deep evolutionary analysis was generated. Of the variant sites, one was found with a conservation score of 2 (Q98R), which indicates a 100% conserved amino acid with greater than 2 standard deviations above the mean for codon selection. Eight of the amino acid variant sites are in regions with a conservation score of 1.5 (Y563N, Y569C, Y569D, Y569H, Y917C, R1070P, R1070Q, and D1270N), and 61 with a score of 1.25-1.0. In total, 70/140 (50%) of the sites fall on amino acids that do not have any nonsynonomous variants throughout evolution. Using our sliding windows of conservation, we were able to determine the top variants for various sized windows: 3 codon window = Q98R, 7 codon window = G551S/D, 15/21/27 codon windows = L1077P.
Expanding pipeline to other rare disease variants
To test our analysis tools for clinical variants, we analyzed several variants predicted outside of our research team, so as to not bias our data presentation, and to make our data predictions comparable to other tools in development. The NIH Undiagnosed Diseases Network (UDN) released a preliminary list of genetic variants found in children with rare diseases. We analyzed 18 of the variants through our SSF analysis (Table S2 ). The variant location for each of these genes was structurally assessed, protein domain modeled, run through 1-5 ns MD simulations, interaction partners for the domain predicted, evolutionary analysis performed with ConSurf, and changes to posttranslational modifications due to the variant predicted (Fig. 9) ; 13 of the variants were predicted to significantly alter the conserved structure of the protein, conserved docking site for unknown protein-protein interactions, protein binding motifs, or posttranslational modifications. In all, 5 of the variants had minimal predicted outcomes on molecular function based on the current tools of the analysis. A description of the interpretations for each protein Fig. 8 Deep Sequence-to-Structure-to-Function analysis (dSSa) pipeline analysis for CFTR. From top left to bottom right. The model for CFTR was generated using I-TASSER, inserted into a simulation square, lipid membrane added, and water equilibrated on both sides of the membrane. The model was then run for 4 ns of molecular dynamic simulations(mds). Each variant from Supplemental Table S1 for cystic fibrosis was generated and energy minimized followed by statistical analysis of protein change. The model was then used to generate homology models for mouse (gray) and rat (red). Open reading frame (ORF) analysis was then performed for evolution analysis with the human marked with a red square in order to generate conservation scores for each amino acid or for various sliding windows of the conservation. Finally, this evolution was used to map conservation onto the protein structure using ConSurf (Fig. 9) can be found in column G of Table S2 under BdSSFa Predicted Impact.Â nalysis of nonsense mutations and frameshift mutations, such as p.E26* in ATXN3L or p.V92Serfs*38 in YPEL3, can generate a list of protein interactions, functional motifs, and posttranslational modification sites that are found in the protein following the early stop codon. Essentially, the SSF tools serve as predictors of molecular functions, and control of these functions for each protein, always identifying molecular outcomes. Analysis of missense mutations is more finite in prediction, providing insight into detailed changes. Some of the variants significantly alter the hydrophobic collapse of a protein's structure, such as p.W98R in CIR1, or variants contributing to structural organization, such as metal binding or disulfide bond formation, e.g., p.C318R in BHLHB9. Other variants are found on surface-exposed sites where conserved protein-protein binding sites are predicted, such as p.I1170T of NCAPD2, and even conserved binding sites that may have controllable posttranslational modifications altered, such as p.R1465W in BAI2 and p.S424P in CALCRL. Finally, the linear motif analysis and posttranslational modifications that are gained by genetic variants, such as p.G1890V in DNAH1 and p.F328V in SCN2A, represent the potential for gain-offunction variants that are incredibly underrepresented in current variant analysis tools.
Discussion
Genomic sequencing is becoming a powerful tool in understanding how genetic variation can result in disease. However, to go from simply detection of a variant, to detailed atomic understanding of the mechanisms altered by such a variant, requires additional tools. In this study, we have taken a highly publicized clinical genomic sequencing case from our group, XIAP C203Y, and assessed the applicably of molecular modeling to understanding how atomic mechanisms may be altered in the disease progression. Analysis of clinically relevant XIAP BIR2 domain variants show that several fall in highly conserved sites that contribute to either the Zn coordinated structure (C203Y) or the folding of the domain (R166I, W173G, G188E, V198M, and L207P). Several additional early stop codon (E99X, Q104X, E118X, and Q171X) or frame shift mutations have been identified that result in the complete removal of the BIR2 and subsequent domains, resulting in disease. In this paper, we also analyzed all known variants in XIAP seen in the genome sequencing for somatic mutations in cancer (from COSMIC) in the hope of determining if a subset of these genomes may contain any type of variants that result in blockade of the Caspase pathway. Several COSMIC variants were identified to be clustered in the UBA domain of XIAP. COSMIC variants were also seen that could alter the interaction of XIAP with Caspase3, Caspase7, and SMAC proteins based on the known structures of XIAP. None of the variants identified in the disease patients were seen in the COSMIC database.
One worry in using the designed SMAC mimetics in treating cancer is the risk of inducing the secondary GI and immune phenotypes associated with variants in XIAP that were first identified with the C203Y variant in our patient. Additionally, these SMAC mimetics may block the noncaspase dependent pathways of other BIR domain proteins, most of which are not currently characterized. Analysis of all human BIR domains revealed amino acids Q197 and F228 of XIAP to be interesting sites for driving drug specificity to only the BIR2 domain of XIAP and no other BIR-containing proteins. Using the known protein interaction sites, amino acid Q197 interacts with the SMAC N-terminus, while F228 does not interact with any part of SMAC. On the contrary, amino acid F228 directly contacts both Caspase-3 and Caspase7, while Q197 does not. Based on our top docking conformation of XIAP BIR2 with RIPK2, neither of these amino acids contributes to binding. Therefore, we suggest that targeting XIAP amino acid F228 and surrounding amino acids with a new Fig. 9 Variants from 17 different genes analyzed with dSSFa. Each model is shown with ConSurf mapping of vertebrate evolutionary analysis for variants listed in Table S2 . The variant location is flagged in each. Colors are based on conservation: gray non-conserved, yellow conserved hydrophobic, red conserved polar acidic, blue conserved polar basic, green conserved hydrophilic class of inhibitors may allow for activation of Caspase while not perturbing the XIAP activation of the NOD2 pathway or other BIR-containing protein pathways.
Following sequencing of a human genome, the time it takes to interpret and propose experiments to validate hypotheses of how the variant results in disease far exceeds that of any conventional clinical test on the market. Many scientists are continuing to push genomic sequencing as a possible clinically based test, especially with the wet lab cost of sequencing reaching several thousand dollars. This opens up the exciting possibility for scientists in the molecular modeling community to help in the interpretation of clinical variants, but will require our community to learn from existing variants and applying new approaches. The research community has numerous tools and resources that can significantly reduce the time it takes to discover the mechanisms in which these clinical variants result in disease phenotype. In the manuscript, we have presented a set of tools developed while studying the detailed mechanisms of XIAP, which could be applied to numerous additional protein variants. To highlight this, we have added analysis of multiple CFTR variants and also a list of 18 separate potential clinical variants for undiagnosed diseases. We have compiled this data and provide all files (alignments, protein models, ConSurf protein mapping, etc.) in the supplemental data for future researchers to use. The databasing of information generated from our dSSFa will thus be able to speed up any future analysis of variants found within the genes we have analyzed. In conclusion, we suggest that the right combination of molecular modeling and additional bioinformatics has the potential to move variant analysis into a hypothesis generator, in which these hypotheses can be tested using additional wet lab experiments.
